Recent news highlights include the FDA acceptance of Mineralys' NDA for lorundrostat in hypertension, positive Phase 2 Explore-OSA trial data, and ongoing clinical and regulatory progress. Market interest has been noted through option activity and stock price movements.

• Mineralys reported its Q4 2025 earnings call transcript on March 12, 2026, discussing clinical progress and financials [N1].
• The FDA accepted Mineralys' NDA submission for lorundrostat for hypertension treatment, with a PDUFA date set for December 22, 2026 [N3][N5].
• Phase 2 Explore-OSA trial data showed clinically meaningful blood pressure reductions and a favorable safety profile in patients with hypertension and obstructive sleep apnea [N5].
• Noteworthy option activity for Mineralys was reported on March 10, 2026, indicating market interest [N4].
• Mineralys stock rose following the FDA acceptance of the NDA for lorundrostat [N3].
• Additional option activity was noted on February 26, 2026, and February 13, 2026, reflecting ongoing investor attention [N6][N7].
• The company broke below its 200-day moving average in February 2026, a technical market indicator [N7].
• Relative strength alerts and oversold conditions were reported in early 2026 and late 2025, respectively, highlighting market volatility [N8].
• Mineralys is advancing lorundrostat toward FDA review and expanding clinical indications [N1].
• After-hours earnings reports on March 12, 2026, included Mineralys among other companies reporting financial results [N2].

Lorundrostat has demonstrated clinically meaningful reductions in systolic blood pressure in pivotal trials with a favorable safety profile, including low incidence of hyperkalemia. The NDA acceptance by the FDA and ongoing open-label extension studies provide momentum toward potential regulatory approval. The drug's selectivity and pharmacokinetic profile may offer advantages over existing therapies, addressing a significant unmet need in patients with uncontrolled or resistant hypertension and related comorbidities. Mineralys' strong liquidity position supports continued development and potential commercialization efforts. Positive clinical data in comorbid conditions such as CKD and OSA may expand the drug's market potential.

Mineralys has not yet generated any revenue and has incurred significant net losses since inception, reflecting the high costs and risks inherent in drug development. Regulatory approval is uncertain and subject to FDA review timelines and potential delays, including risks from government shutdowns or disruptions. The company faces intense competition from larger pharmaceutical companies and generic drugs, which may limit market penetration. Manufacturing and supply chain risks exist due to reliance on third-party contractors. Additionally, Mineralys will require substantial additional capital to fund ongoing operations, and failure to secure financing on favorable terms could adversely impact development and commercialization plans.

Mineralys Therapeutics' moat is based on its proprietary, highly selective aldosterone synthase inhibitor, lorundrostat, which targets a key driver of uncontrolled and resistant hypertension. The compound's clinical data demonstrate robust blood pressure reductions with a favorable safety and tolerability profile, potentially offering advantages over existing mineralocorticoid receptor antagonists that have side effects limiting their use. The company's intellectual property portfolio, including exclusive licensing from Tanabe Pharma, supports protection of lorundrostat. However, the biopharmaceutical industry is highly competitive with multiple companies developing therapies targeting similar pathways, and Mineralys faces competition from larger, better-funded firms and generic drugs. The company's ability to successfully commercialize lorundrostat and maintain competitive advantages will depend on regulatory approval, clinical differentiation, and market acceptance.

• Regulatory Approval Risk: The FDA review process for lorundrostat's NDA may encounter delays or require additional data, which could impact the timing and possibility of approval.
• Clinical Trial Risks: Future clinical trials or ongoing studies may not confirm prior positive results, and adverse safety findings could arise.
• Competition: Mineralys faces competition from established pharmaceutical companies, generic drugs, and other developers of aldosterone-targeting therapies.
• Manufacturing and Supply Chain: Dependence on third-party manufacturers entails risks of supply disruptions, quality control issues, and scaling challenges.
• Capital Requirements: The company has incurred net losses and will need to raise additional capital to fund development and commercialization, which may dilute existing shareholders or impose restrictive covenants.
• Market Acceptance and Reimbursement: Even if approved, lorundrostat's commercial success depends on physician adoption, patient acceptance, pricing, and reimbursement by payors.
• Macroeconomic and Policy Risks: Inflation, trade policies, tax law changes, and government agency disruptions could adversely affect operations and financial condition.

• Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines targeting diseases driven by dysregulated aldosterone, primarily cardiorenal conditions such as hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA).
• Their lead product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) designed to reduce aldosterone levels by inhibiting CYP11B2 enzyme.
• Lorundrostat is being developed for treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN), including in combination with other antihypertensive drugs.
• The company completed five successful clinical trials supporting lorundrostat's efficacy and safety, including two pivotal trials: Phase 3 Launch-HTN and Phase 2 Advance-HTN, demonstrating robust and durable reductions in systolic blood pressure (BP).
• Lorundrostat was well tolerated in clinical trials with a favorable safety profile and low incidence of hyperkalemia.
• The company submitted a New Drug Application (NDA) for lorundrostat in December 2025, which the FDA accepted with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.
• Additional clinical trials include Phase 2 Explore-CKD and Phase 2 Explore-OSA, evaluating lorundrostat in patients with hypertension and comorbid CKD or OSA, showing clinically meaningful BP reductions and favorable safety.
• Mineralys licensed lorundrostat from Tanabe Pharma Corporation under an exclusive worldwide license with milestone and royalty payment obligations.
• The company has not yet defined its sales, marketing, or product distribution strategy for lorundrostat, considering options including strategic partners or own sales force.
• The biopharmaceutical industry is competitive with multiple companies developing therapies for hypertension and related conditions; Mineralys faces competition from larger, better-funded companies and generic drug classes.
• Mineralys has raised approximately $1.1 billion in gross proceeds since inception through equity and convertible securities.
• As of December 31, 2025, Mineralys had cash, cash equivalents, and investments totaling approximately $656.6 million.
• For the fiscal year ended December 31, 2025, the company reported a net loss of $154.7 million and basic and diluted EPS of -$2.29 per share.
• The company had a current ratio of 43.76 and a cash ratio of 43.45 as of December 31, 2025, indicating strong liquidity.
• Mineralys has incurred net losses and negative cash flows from operations since inception and expects expenses to increase as it advances clinical trials, regulatory approval, and commercialization efforts.
• Risks include potential delays or adverse outcomes in clinical trials, regulatory approval uncertainties, competition, manufacturing and supply chain risks, and the need for additional capital.
• The company disclosed risks related to inflation, trade policies, FDA and government agency disruptions, and changes in tax laws that could affect operations and financial condition.
• Mineralys management team has extensive experience in drug discovery, development, and commercialization from prior roles at major pharmaceutical companies.
• Recent news highlights include FDA acceptance of the NDA for lorundrostat, positive Phase 2 Explore-OSA trial data, and ongoing pivotal program results.
• The company is conducting an open-label extension trial (Transform-HTN) to obtain long-term efficacy and safety data for lorundrostat.
• The NDA acceptance and clinical trial results have generated notable market interest and option activity as reported in recent news.
• Mineralys has no products approved for sale and has not generated revenue to date; it plans to finance operations through equity offerings, debt, or collaborations until product commercialization.
• The company faces risks from potential government shutdowns or global health emergencies that could delay regulatory review processes.
• Mineralys is subject to intellectual property risks and competition from other companies developing aldosterone synthase inhibitors and mineralocorticoid receptor antagonists.
• The company’s clinical data suggest lorundrostat may offer advantages over existing mineralocorticoid receptor antagonists in efficacy, safety, and tolerability.
• The company’s NDA targets hypertension treatment in combination with other antihypertensive drugs, addressing a large unmet medical need in patients with uncontrolled or resistant hypertension.